Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma

Immunotherapy

Volumn 4, Issue 5, 2012, Pages 477-481

  Muccioli, Maria ^a   Longstaff, Caitlin ^b   Benencia, Fabian ^a,b,c  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c Ohio University   (United States)

Author keywords

helpless CD8 cells; immunotherapy; melanoma; Tregs

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPLESS CD8+ T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; TUMOR MODEL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS;

EID: 84861660583     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.39     Document Type: Article

References (38)

1. Denardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9(4), 212 (2007).
2. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26(3-4), 373-400 (2007).
3. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: The role of tumor invading T cells. World J. Gastroenterol. 12(45), 7233-7238 (2006).
4. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
5. Oble DA, Loewe R, Yu P, Mihm MC. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 9, 3 (2009).
6. 8+ T cells in combination with low-dose interferon a. Cancer Immunol. Immunother. 60(7), 953-963 (2011).
7. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-Activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N. Engl. J. Med. 313(23), 1485-1492 (1985).
8. Dutcher JP, Creekmore S, Weiss GR et al. A Phase II study of interleukin 2 and lymphokine-Activated killer cells in patients with metastatic malignant melanoma. J. Clin. Oncol. 7(4), 477-485 (1989).
9. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin 2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77(1), 89-96 (1996).
10. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12), 907-913 (1994).
11. Muranski P, Boni A, Wrzesinski C et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat. Clin. Pract. Oncol. 3(12), 668-681 (2006).
12. Mazzarella T, Cambiaghi V, Rizzo N et al. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: Clinical implications for adoptive cell transfer therapy. Cancer Immunol. Immunother. doi:10.1007/ s00262-011-1179-z (2011) (Epub ahead of print).
13. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26(4), 332-342 (2003).
14. Nguyen LT, Yen PH, Nie J et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS ONE 5(11), e13940 (2010).
15. Ruegg C. Leukocytes, inflammation, and angiogenesis in cancer: Fatal attractions. J. Leukoc. Biol. 80(4), 682-684 (2006).
16. Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J. Pathol. 208(2), 233-248 (2006).
17. Szabo E, Paska C, Kaposi Novak P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol. Oncol. Res. 10(1), 5-11 (2004).
18. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
19. 25+ immunoregulatory T cells: Central players in the arena of peripheral tolerance. Semin. Immunol. 16(2), 81-88 (2004).
20. 4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4), 345-352 (2005).
21. 4+ regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. 305, 51-66 (2006).
22. 4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174(5), 2591-2601 (2005).
23. Jacobs JF, Nierkens S, Figdor CG, De Vries IJ, Adema GJ. Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol. 13(1), e32-e42 (2012).
24. Raghavan S, Quiding-Jarbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev. Gastroenterol. Hepatol. 5(4), 489-501 (2011).
25. 25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32(11), 3267-3275 (2002).
26. 25+ regulatory T cells. J. Immunol. 174(1), 90-98 (2005).
27. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200(6), 771-782 (2004).
28. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128(11), 2596-2605 (2008).
29. Salem ML, Cole DJ. Dendritic cell recovery post-lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination. Cancer Immunol. Immunother. 59(3), 341-353 (2010).
30. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv. Surg. 45, 341-360 (2011).
31. Wrzesinski C, Restifo NP. Less is more: Iymphodepletion followed by hematopoietic stem cell transplant augments adoptive T cell-based anti-tumor immunotherapy. Curr. Opin Immunol. 17(2), 195-201 (2005).
32. Perret R, Ronchese F. Memory T cells in cancer immunotherapy: Which CD8 T cell population provides the best protection against tumours? Tissue Antigens 72(3), 187-194 (2008).
33. Côté AL, Byrne KT, Steinberg SM, Zhang P, Turk MJ. Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS ONE 6(10), e26491 (2011).
34. 8+ memory T cell responses to mouse melanoma. J. Clin. Invest. 121(5), 1797-1809 (2011).
35. Wallace A, Kapoor V, Sun J et al. Transforming growth factor b receptor blockade augments the effectiveness of adoptive T cell therapy of established solid cancers. Clin. Cancer Res. 14(12), 3966-3974 (2008).
36. Whitmire JK, Murali-Krishna K, Altman J, Ahmed R. Antiviral CD4 and CD8 T cell memory: Differences in the size of the response and activation requirements. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 355(1395), 373-379 (2000).
37. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300(5617), 339-342 (2003).
38. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J. Immunol. 170(4), 2053-2063 (2003).